JB Chemicals & Pharmaceuticals (JBCPL) Q3FY23 performance was broadly in line with our estimates, driven by robust growth across the segments. Consolidated revenue grew 32% YoY to Rs7.9bn (I-Sec: 7.7bn) driven by acquisitions in India.